489 TWT-101: a phase 1 study of the novel HPK1 inhibitor CFI-402411 in patients with advanced cancer

• Judy Wang,
• Omid Hamid,
• Siqing Fu,
• Johanna Bendell,
• Anna Spreafico,
• Alexander Spira,
• Kyriakos Papadopoulos,
• Brigette Ma,
• Mark Bray,
• Graham Fletcher,
• Glenn Michelson,
• Emily Roberts-Thomson

Affiliations

Judy Wang

1 Vascular Surgery, Northern Hospital, Epping, Victoria, Australia

Omid Hamid

Cedars-Sinai Medical Center Angeles Clinic and Research Institute, Santa Monica, California, USA

Siqing Fu

2 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Johanna Bendell

Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee, USA

Anna Spreafico

Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Alexander Spira

Department of Medical Oncology, Virginia Cancer Specialists, Fairfax, Virginia, USA

Kyriakos Papadopoulos

4START – San Antonio., San Antonio, TX, USA

Brigette Ma

6The Chinese University of Hong Kong, Sha Tin, Hong Kong

Mark Bray

9Treadwell Therapeutics, Toronto, Canada

Graham Fletcher

9Treadwell Therapeutics, Toronto, Canada

Glenn Michelson

9Treadwell Therapeutics, Toronto, Canada

Emily Roberts-Thomson

9Treadwell Therapeutics, Toronto, Canada